Preclinical News and Research

RSS
Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

Helsinn, Mundipharma sign distribution and license agreement for investigational therapy

LSDF announces research and development grants to commercialize health-related technologies

LSDF announces research and development grants to commercialize health-related technologies

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

TGen, Nemucore, and Barrow collaboration aims for new drugs to treat glioblastoma

Merck signs license agreement with CNIO for cancer drug development

Merck signs license agreement with CNIO for cancer drug development

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

BioLineRx enrolls first patient in BL-7010 Phase 1/2 trial for treatment of celiac disease

New projects advance treatments for radiation syndrome, cardiac arrest-induced brain injury and rare blood disorder

New projects advance treatments for radiation syndrome, cardiac arrest-induced brain injury and rare blood disorder

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Researchers use ATX-Red AR-2 as new imaging agent to illuminate tumors

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

BioLineRx reports promising initial results from Phase 2 trial of BL-8040 in AML patients

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Stem cell technology: an interview with Professor Igor Slukvin, University of Wisconsin-Madison and scientific founder of CDI and Cynata

Cetuximab fails in second-line combination for recurrent NSCLC

Cetuximab fails in second-line combination for recurrent NSCLC

Study: Antisense drugs show activity in wide range of tissues and organs

Study: Antisense drugs show activity in wide range of tissues and organs

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

Z-endoxifen may provide better treatment for women with estrogen positive breast cancer

Retrophin to acquire privately-held company, Kyalin Biosciences

Retrophin to acquire privately-held company, Kyalin Biosciences

Retrophin signs agreement with Novartis for exclusive U.S. license for Syntocinon Nasal Spray

Retrophin signs agreement with Novartis for exclusive U.S. license for Syntocinon Nasal Spray

New mechanism explains why anti-tumor activity of specific immune suppressed during tumor growth

New mechanism explains why anti-tumor activity of specific immune suppressed during tumor growth

NIH data-sharing may advance genetic and translational research, therapeutic target discovery

NIH data-sharing may advance genetic and translational research, therapeutic target discovery

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.